Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Not Confirmed
Not Confirmed
12-14 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Not Confirmed
12-14 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
12 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-third-quarter-2024-financial-results-and-narrows-financial-guidance-302302018.html
10 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/heron-therapeutics-reaffirms-availability-and-ample-supply-of-cinvanti-sustol-and-aponvie-as-alternatives-during-the-potential-shortage-of-intravenous-fluids-302273403.html
25 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-fda-approval-of-the-prior-approval-supplement-application-for-zynrelef-vial-access-needle-van-302258083.html
03 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-appointment-of-brett-fleshman-as-chief-business-officer-302236304.html
03 Sep 2024
// CONTRACT PHARMA
https://www.contractpharma.com//contents/view_breaking-news/2024-09-03/heron-therapeutics-taps-brett-fleshman-as-chief-business-officer/?widget=listSection
15 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-the-inclusion-of-zynrelef-as-a-qualifying-product-under-the-proposed-2025-non-opioid-policy-for-pain-relief-under-the-opps-and-the-asc-payment-system-302196793.html
Details:
Zynrelef (bupivacaine, meloxicam) is an investigational local anesthetic given periarticularly as an extended-release solution for postoperative pain.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Mayo Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Mayo Clinic
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves ZYNRELEF® Vial Access Needle by Heron Therapeutics
Details : Zynrelef (bupivacaine, meloxicam) is an investigational local anesthetic given periarticularly as an extended-release solution for postoperative pain.
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2024
Details:
Zynrelef (bupivacaine, meloxicam) is an investigational local anesthetic given periarticularly as an extended-release solution for postoperative pain. The FDA has set a PDUFA date of 23 Sep 2024.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Mayo Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Mayo Clinic
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Accepts Prior Approval Supplement for ZYNRELEF® Vial Access Needle
Details : Zynrelef (bupivacaine, meloxicam) is an investigational local anesthetic given periarticularly as an extended-release solution for postoperative pain. The FDA has set a PDUFA date of 23 Sep 2024.
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2024
Details:
Company submmitted Prior Approval Supplement to the FDA for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle kit.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Submits ZYNRELEF® Vial Access Needle for FDA Approval
Details : Company submmitted Prior Approval Supplement to the FDA for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle kit.
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Details:
The partnership aims to expand the sales network supporting Zynrelef (bupivacaine and meloxicam) extended-release solution, the first and only dual-acting local anesthetic, for post-operative pain.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Recipient: CrossLink Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2024
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : CrossLink Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Heron Partners With CrossLink Life Sciences To Expand Promotional Effort For ZYNRELEF®
Details : The partnership aims to expand the sales network supporting Zynrelef (bupivacaine and meloxicam) extended-release solution, the first and only dual-acting local anesthetic, for post-operative pain.
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 07, 2024
Details:
ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newl...
Details : ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 29, 2022
Details:
Administered via a single 30-second IV injection, APONVIE(aprepitant) reaches drug levels associated with ≥97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours.
Lead Product(s): Aprepitant
Therapeutic Area: Gastroenterology Brand Name: Aponvie
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Posto...
Details : Administered via a single 30-second IV injection, APONVIE(aprepitant) reaches drug levels associated with ≥97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours.
Brand Name : Aponvie
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2022
Details:
ZYNRELEF (bupivacaine) is first and only therapy for pain management to be rigorously tested demonstrated superiority to bupivacaine solution, and sustained postoperative pain relief for up to 72 hours and decreased need for opioids, with more patients opioid-free.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative N...
Details : ZYNRELEF (bupivacaine) is first and only therapy for pain management to be rigorously tested demonstrated superiority to bupivacaine solution, and sustained postoperative pain relief for up to 72 hours and decreased need for opioids, with more patients o...
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2022
Details:
New interim data from Phase 2 study suggests ZYNRELEF (bupivacaine) was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatolo...
Details : New interim data from Phase 2 study suggests ZYNRELEF (bupivacaine) was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections.
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2022
Details:
ZYNRELEF is first and only therapy of dual-acting fixed-dose combination of local anesthetic bupivacaine and a low dose of meloxicam, for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine solution.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postope...
Details : ZYNRELEF is first and only therapy of dual-acting fixed-dose combination of local anesthetic bupivacaine and a low dose of meloxicam, for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine ...
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2022
Details:
ZYNRELEF is an extended-release solution of bupivacaine and meloxicam that is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Neurology Brand Name: Zynrelef
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Lead Product(s) : Bupivacaine,Meloxicam
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Heron Therapeutics Announces Publication of Results from HOPE Trial for ZYNRELEF™
Details : ZYNRELEF is an extended-release solution of bupivacaine and meloxicam that is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and tota...
Brand Name : Zynrelef
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 28, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?